Abstract
Light therapy has been accepted as a promising therapeutic choice for depression. Positron emission tomography (PET) combined with specific radiotracers has great benefits for revealing pathogenesis and developing therapeutics. This study aimed to investigate the influences of light therapy on microglial activation and glucagon-like peptide-1 receptor (GLP-1R) expression in the brain of depressive rats using [18F]DPA-714 and [18F]exendin-4 PET. The results showed that chronic unpredictable mild stress (CUMS)-induced depressive rats had poorer performance in behavioral tests compared to normal rats (p < 0.05) and the depressive-like behavior could be ameliorated by light therapy. Besides, depressive rats had significantly higher [18F]DPA-714 uptake and lower [18F]FDG uptake compare to normal rats in 11 and 9 regions of interest (ROIs) of the brain, respectively (p < 0.05). After 5 weeks of light therapy, higher [18F]FDG and [18F]exendin-4 uptake was observed in most ROIs of light therapy-treated depressive rats compared to untreated depressive rats (p < 0.05) and no significant differences existed in [18F]DPA-714 uptake between the two groups. This study demonstrated that light therapy can ameliorate depressive-like behavior, improve glucose metabolism, and halt the decline of brain GLP-1R expression of depressive rats, but have no effects on microglial activation caused by CUMS. Besides, this study validated that [18F]DPA-714 and [18F]exendin-4 PET have the potential for noninvasive evaluation of microglial activation and GLP-1R expression in the brain of depression.
Highlights
In the past few years, light therapy has been accepted as an optional therapeutic choice for some neuropsychiatric disorders such as major depressive disorder, circadian phase sleep disorder, Parkinson’s disease, and Alzheimer’s disease[1,2,3,4,5]
We firstly evaluated the feasibility of glucagon-like peptide-1 receptor (GLP-1R) Positron emission tomography (PET) in the brain using [18F]AlFNOTA-MAL-Cys39-exendin-4 ([18F]exendin-4) and demonstrated the influences of age on GLP-1R expression[32]
No significant differences in the [18F]exendin-4 uptake could be quantified in any regions of interest (ROIs) between LT group and baseline (Fig. 4a and Supplementary Table S5). These results suggested that light therapy prevented the decrease of GLP-1R expression in the brain of chronic unpredictable mild stress (CUMS)-induced depressive rats
Summary
In the past few years, light therapy has been accepted as an optional therapeutic choice for some neuropsychiatric disorders such as major depressive disorder, circadian phase sleep disorder, Parkinson’s disease, and Alzheimer’s disease[1,2,3,4,5]. The mechanisms of light therapy for depression remain unclear and there is a lack of efficacy evaluation methods for this treatment. A levels and serotonin transporter binding potential in patients with depression after a few weeks of bright light therapy using [11C]harmine and [11C]DASB PET imaging[6,7]. The inflammatory hypothesis in depression has received lots of attention in recent years. Numerous studies illustrated that depression may be associated with microglial activation and neuroinflammation[8,9].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
